-2.png?width=25&height=25&name=21%20Featured%20Image%20specs%20(1)-2.png){kind=small}
The content of this blog is designed and intended for the education of Healthcare Professionals
The latest toxin taking the world by storm has arrived in Australia - and Fresh Clinics is the first to access it for their Members.
Meet Evolus, not only the newest toxin in 10 years, but a visionary in performance beauty, challenging conventions, and inspiring transformation. Evolus began its journey back in 2013. After rigorous clinical trials involving over 2,100 patients, their efforts culminated in approval in the US, Canada, and Europe. By 2023, the product earned approval from the TGA in Australia.
Unlike traditional pharmaceutical companies, Evolus is dedicated to creating innovative products for medical aesthetics clinicians. As part of their global expansion, they have launched Nuceiva® (prabotulinumtoxinA) in Australia, adding to their successful presence in the United States, Canada, and Europe.
Fresh Clinics recently hosted the much-anticipated Evolus launch, exclusive to Fresh Members. We put together a recap of the event, and how this latest toxin is about to transform the landscape of aesthetic treatments.
Dr John Delaney, calling in live from Fresh Clinics headquarters in North Sydney, encapsulated the significance of the launch perfectly: "What’s pretty remarkable about this session is it’s all coming to you live from Fresh Clinics.” This marked the first live product demonstration at our HQ.
Evolus isn’t your regular pharmaceutical company; it's a performance beauty company dedicated exclusively to medical aesthetics, striving to evolve the future of beauty. Daniel Henry, General Manager for Evolus Australia, highlighted the ethos behind the company: "We are Evolus, where artistry meets science. We are a movement against the ordinary."
Clinical Data
Dr David Eccleston, calling in from the UK shared insightful clinical data, emphasising the success behind the development of this product. The large-scale trials demonstrated that Nuceiva® could stand toe-to-toe with market toxin leaders... “87% of subjects achieved the target of at least one improvement at day 30 compared to 83% of subjects in the competitor's group,” Dr Eccleston shared, underlining the product’s efficacy.
Key points also included:- Immunogenicity: Nuceiva® showed 0 cases of neutralising antibodies, unlike many of its competitors
- Patient Satisfaction: Feedback from patients was overwhelmingly positive, with many noting quicker onset and longer duration of results, coupled with a more natural look
Hands-On Demonstration
Amber Pappas, Director of Medical Affairs at Evolus, treated us to a behind-the-scenes tour of the Evolus Bus in Denver. This innovative setup includes anatomy labs, silicone simulations, and educational events for medical professionals. Amber provided detailed demonstrations of injection techniques with Nucevia®, using their advanced tools and model.
Our very own Dr John Holbrook performed a live demo from Fresh Clinics HQ, explaining the procedure and best practices. He emphasised the importance of delivering toxin where the muscles are, ensuring effective and safe results for patients.
Evolus CEO David Moatazedi summed up the company’s approach: "We saw an opportunity to create a company that operates differently. We're dedicated to cash pay, we're digitally powered and forward-thinking. And we have a modern edgy brand made with the 900 kDa (Kilodalton) molecule." This commitment to innovation and patient satisfaction is what sets Evolus apart.
In today’s competitive market, Evolus stands out with its innovative approach and commitment to patient satisfaction. Their investment in cutting-edge technology and high-purity processes ensures that their products are not just effective but also safe. For clinicians and patients alike, Evolus' entry into the Australian market promises a new standard in aesthetic treatments.